The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients

Disease Markers

Volumn 21, Issue 3, 2005, Pages 127-132

  Dworacka, Marzena ^a   Winiarska, Hanna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

1,5 anhydro D glucitol; Diabetes mellitus type 2; Glycated haemoglobin; Postprandial hyperglycaemia

Indexed keywords

1,5 ANHYDROSORBITOL; DIAPREL; GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CALCULATION; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIAGNOSTIC VALUE; DIET RESTRICTION; DISEASE CONTROL; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; POSTPRANDIAL STATE; PRIORITY JOURNAL;

LAKE VICTORIA MARBURGVIRUS;

EID: 27644518418     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/251068     Document Type: Article

References (20)

1. T. Yamanouchi and Y. Tachibana, Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body, Am. J. Physiol. 264 (1992), E268-E273.
2. Y. Akanuma and M. Morita, Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients, Diabetologia 11 (1988), 831-835.
3. J.B. Buse and J.L.R. Freeman, Serum 1,5-anhydroglucitol (GlycoMarkTM): A short-term glycemic marker, Diabetes Technol. Ther. 5 (2003), 355-363.
4. D. Stickle and J. Turk, A kinetic mass balance model for 1,5-anhydroglucitol: Applications to monitoring of glycemic control, Am. J. Physil. 273 (1997), E821-E830.
5. M. Kishimoto and Y. Yamasaki, 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM, Diabetes Care 18 (1995), 1156-1159.
6. M. Dworacka and H. Winiarska, 1,5-Anhydro-D-glucitol: A novel marker of glucose excursions, Int. J. Clin. Pract. suppl 19 (2002), 40-44.
7. 1c level, Diabetes Care 23 (2000), 1830-1834.
8. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group, Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria, Arch. Intern. Med. 161 (2001), 397-405.
9. European Diabetes Policy Group 1999, A desktop guide to Type 2 diabetes mellitus, Diabet. Med. 16 (1999), 716-730.
10. 1c) in screening for undiagnosed diabetes in the US population, Diabetes Care 23 (2000), 187-191.
11. 1c, 23 (2003).
12. M. Yabuuchi and M. Masuda, Simple enzymatic method for determining 1,5-anhydro-D-glucitol for diagnosis of diabetes mellitus, Clin. Chem. 35 (1984), 2039-2943.
13. M. Dworacka and K. Szczawińska, The application of enzymatic method for 1,5-anhydro-D-glucitol estimation in plasma, Diagnostyka Laboratoryjna 33 (1997), 269-276.
14. J. Schlichtkrull and O. Munck, The M-value, an index of blood-sugar control in diabetics, Acta. Med. Scand. 177 (1965), 95-102.
15. P.J. Dunn and R.A. Cole, Temporal relationship of glycosylated haemoglobin concentrations to glucose control in diabetes, Diabetologia 17 (1979), 213-220.
16. 1c and overall blood glucose control? Diabetes Care 24 (2001), 2011 (letter).
17. M. Bouma and J.H. Dekker, How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin using patients with type 2 diabetes? Diabetes Care 22 (1999), 904-907.
18. 1c interrelatioships in type 2 diabetes, Diabetes Care 24 (2001), 2023-2029.
19. P.J. Higgins and H.F. Bunn, Kinetic analysis of nonenzymatic glycosylation of hemoglobin, J. Biol. Chem. 256 (1981), 5204-5208.
20. J.B. Meigs and D.M. Nathan, Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham offspring study, Diabetes Care 25 (2002), 1845-1850.